Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Condition:   Cervical Cancer Intervention:   Drug: Nimotuzumab、Tislelizumab Sponsor:   Peking Union Medical College Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials